Stryker Corporation $SYK Shares Purchased by McAdam LLC

McAdam LLC raised its position in shares of Stryker Corporation (NYSE:SYK) by 5.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 663 shares of the medical technology company’s stock after buying an additional 35 shares during the quarter. McAdam LLC’s holdings in Stryker were worth $262,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Pitti Group Wealth Management LLC raised its stake in Stryker by 3.2% during the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after buying an additional 27 shares in the last quarter. Missouri Trust & Investment Co raised its position in shares of Stryker by 15.7% during the 2nd quarter. Missouri Trust & Investment Co now owns 1,769 shares of the medical technology company’s stock worth $700,000 after purchasing an additional 240 shares during the period. Verum Partners LLC raised its position in shares of Stryker by 7.8% during the 2nd quarter. Verum Partners LLC now owns 733 shares of the medical technology company’s stock worth $290,000 after purchasing an additional 53 shares during the period. TD Private Client Wealth LLC raised its position in shares of Stryker by 8.7% during the 2nd quarter. TD Private Client Wealth LLC now owns 5,902 shares of the medical technology company’s stock worth $2,335,000 after purchasing an additional 473 shares during the period. Finally, Carr Financial Group Corp raised its position in shares of Stryker by 12.2% during the 2nd quarter. Carr Financial Group Corp now owns 691 shares of the medical technology company’s stock worth $274,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on SYK shares. Truist Financial set a $415.00 price target on Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Evercore ISI increased their price target on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. Finally, Needham & Company LLC raised their target price on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Fourteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $430.33.

Stryker Stock Up 0.1%

SYK opened at $368.83 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $141.01 billion, a P/E ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. The stock’s 50 day moving average price is $385.71 and its 200 day moving average price is $378.97.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.